TCBP

TC BioPharm
TCBP

$6.23

6.32%

Market Cap: $3.56M

About: TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

Employees: 41

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

81% more capital invested

Capital invested by funds: $42.6K [Q1] → $77K (+$34.4K) [Q2]

60% more funds holding

Funds holding: 5 [Q1] → 8 (+3) [Q2]

0.03% more ownership

Funds ownership: 0.07% [Q1] → 0.09% (+0.03%) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for TCBP.

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about TCBP published over the past 30 days

TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial

No TCB008-related Adverse Events seen in any of the re-start patients 6 Patients received second dose, 3 Patients received third dose, 1 Patient received fourth dose EDINBURGH, Scotland, Sept. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial ongoing in the UK with no drug related Adverse Events seen in any of the re start patients.

TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial

TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox

EDINBURGH, Scotland , Sept. 9, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox.

TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox

TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox

EDINBURGH, Scotland , Sept. 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox.

TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox

TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

EDINBURGH, Scotland , Sept. 5, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications today announced it will participate at the H.C.

TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

TCBP Announces Dosing of 5 New Patients in ACHIEVE

5 New patients dosed, bringing total to 6 patients dosed in ACHIEVE at higher dose level 5 Patients received second dose 2 Patients received third dose EDINBURGH, Scotland , Sept. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces dosing of 5 new patients in the ACHIEVE Phase 2b trial ongoing in the UK.

TCBP Announces Dosing of 5 New Patients in ACHIEVE

TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering

EDINBURGH, Scotland , Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of its previously announced public offering, upsized to 6,000,000 shares of its American Depository Shares ("ADSs")(or pre-funded warrants in lieu thereof), together with Series H warrants ("Series G Warrants") to purchase up to 6,000,000 ADSs at a combined public offering price of $1 per ADS (or pre-funded warrant in lieu thereof) and associated Series H Warrant. The Series H Warrants have an exercise price of £0.76 per ADS, are exercisable upon issuance and will expire one year from the date of issuance.

TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering

TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications

EDINBURGH, Scotland , Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has received a patent grant from European Patent Office (EPO) covering the use of modified gamma delta cells for the treatment of cancer and viral indications. The Company intends to proceed with the patent process in specific European countries in line with the commercial strategy of TCBP.

TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications

TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b)

EDINBURGH, Scotland , Aug. 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the Company has regained compliance with the Nasdaq Stock Market Listing Rule 5550(b) which will maintain the listing of the Company's American depositary shares on the Nasdaq Global Select Market. On May 24, 2024, the Company received written notification from the listing qualifications staff of the Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company was not in compliance with the Minimum Stockholders' Equity Requirement, as of March 31, 2024.

TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b)

TC BioPharm Announces Closing of $2.0 Million Public Offering

EDINBURGH, Scotland , Aug. 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of its previously announced public offering of 2,000,000 shares of its American Depository Shares ("ADSs")(or pre-funded warrants in lieu thereof), together with Series G warrants ("Series G Warrants") to purchase up to 2,000,000 ADSs at a combined public offering price of $1 per ADS (or pre-funded warrant in lieu thereof) and associated Series G Warrant. The Series G Warrants have an exercise price of £0.78 per ADS, are exercisable upon issuance and will expire one year from the date of issuance.

TC BioPharm Announces Closing of $2.0 Million Public Offering

Why Is TC BioPharm (TCBP) Stock Down 46% Today?

TC BioPharm (NASDAQ: TCBP ) stock is falling on Wednesday after the clinical-stage biopharmaceutical company announced the pricing of a registered direct offering of its shares. TC BioPharm is selling 2 million of its American Depository Shares (ADS) for $1 per share.

Why Is TC BioPharm (TCBP) Stock Down 46% Today?

See News Rankings